Revolution Medicines (MIL:1RVMD) Beginning Cash Position: €337.31 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1RVMD Revolution Medicines Inc MIL:1RVMD
9 GF Score
Price €178.40
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Revolution Medicines Beginning Cash Position?

Revolution Medicines MIL:1RVMD +4.60% 9 Beginning Cash Position is €337.31 Mil as of Jun. 2026. GuruFocus rates MIL:1RVMD with a GF Score™ of 9/100 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Revolution Medicines's Beginning Cash Position for the quarter that ended in Jun. 2026 was €337.31 Mil.

Revolution Medicines's quarterly Beginning Cash Position increased from Dec. 2025 (€189.84 Mil) to Mar. 2026 (€336.14 Mil) and increased from Mar. 2026 (€336.14 Mil) to Jun. 2026 (€337.31 Mil).

Revolution Medicines's annual Beginning Cash Position increased from Dec. 2023 (€149.61 Mil) to Dec. 2024 (€667.72 Mil) but then declined from Dec. 2024 (€667.72 Mil) to Dec. 2025 (€466.94 Mil).

Revolution Medicines Beginning Cash Position Related Terms

Revolution Medicines Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Revolution Medicines's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Revolution Medicines Beginning Cash Position Chart

Revolution Medicines Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only 93.24 104.06 149.61 667.72 466.94

Revolution Medicines Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 292.40 346.21 189.84 336.14 337.31
MIL:1RVMD
9GF Score
Revolution Medicines Inc MIL:1RVMD
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Revolution Medicines Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of €337.31 Mil mean?
Revolution Medicines (MIL:1RVMD) has a Beginning Cash Position of €337.31 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Revolution Medicines and its competitors.
Is Revolution Medicines' Beginning Cash Position too high?
Revolution Medicines' current Beginning Cash Position is €337.31 Mil. Overall, Revolution Medicines has a GF Score™ of 9/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Revolution Medicines' Beginning Cash Position compare to ALNY and ONC?
Revolution Medicines' Beginning Cash Position of €337.31 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Revolution Medicines and its competitors. Revolution Medicines's current Beginning Cash Position is €337.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revolution Medicines stock overvalued right now?
Based on GuruFocus' analysis, Revolution Medicines (MIL:1RVMD) is currently considered Significantly Overvalued. The current Beginning Cash Position is €337.31 Mil. Revolution Medicines' overall GF Score™ is 9/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Revolution Medicines (MIL:1RVMD), the current Beginning Cash Position is €337.31 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Revolution Medicines Business Description

Other Exchanges RVMD:USA42Z:Germany
Address 700 Saginaw Drive, Redwood City, CA, USA, 94063
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
9GF Score

Get the complete analysis for MIL:1RVMD

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€178.40
Price